,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-10-04 23:16:00,The Zacks Research Daily presents the best research output of our analyst team.,0.6325156092643738,0.012341027148067951,0.35514333844184875,positive,0.6201745867729187
1,2018-10-04 23:16:00,"Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Bristol-Myers (BMY) and Costco (COST).",0.03659414127469063,0.00802411325275898,0.9553817510604858,neutral,0.028570028021931648
2,2018-10-04 23:16:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
3,2018-10-04 23:16:00,"You can see all of today's research reports here >>>

Buy-ranked Home Depot 's shares have gained +19.9% over the past year, marginally underperforming the Zacks Retail Building Products industry's +20.9% increase.",0.9228290915489197,0.056695666164159775,0.020475244149565697,positive,0.866133451461792
4,2018-10-04 23:16:00,"The Zacks analyst thinks that this performance is attributable to its five-year long trend of beating earnings estimates, which continued in second-quarter fiscal 2018.",0.8927931189537048,0.03878362104296684,0.06842324137687683,positive,0.8540095090866089
5,2018-10-04 23:16:00,"Moreover, sales reverted to a positive surprise trend after a miss in the last-reported quarter.",0.835457980632782,0.07232441008090973,0.0922175794839859,positive,0.7631335854530334
6,2018-10-04 23:16:00,Results gained from a rebound in the seasonal business that impacted sales in the fiscal first quarter and the solid execution.,0.951236367225647,0.021720444783568382,0.0270431786775589,positive,0.9295158982276917
7,2018-10-04 23:16:00,"Further, its relentless focus on affording innovative products, boosting interconnected customer experience and driving productivity seems to be paying off.",0.9182772040367126,0.0140379061922431,0.0676848292350769,positive,0.904239296913147
8,2018-10-04 23:16:00,A steady housing market recovery and strong customer demand also remain tailwinds.,0.2597901523113251,0.6092572212219238,0.1309526115655899,negative,-0.34946706891059875
9,2018-10-04 23:16:00,"Backed by the solid performance in the first half of fiscal 2018, the company raised the earnings and sales forecast for fiscal 2018.",0.911295473575592,0.018950916826725006,0.06975354999303818,positive,0.8923445343971252
10,2018-10-04 23:16:00,"However, commodity cost inflation in various categories, including rising raw material and transportation costs as well as recently enacted tariffs are likely to pressure margins.",0.041271477937698364,0.680564284324646,0.27816423773765564,negative,-0.63929283618927
11,2018-10-04 23:16:00,(You can read the full research report on Home Depot here >>> ).,0.012610534206032753,0.013505421578884125,0.973884105682373,neutral,-0.0008948873728513718
12,2018-10-04 23:16:00,"Shares of Buy-ranked Bristol-Myers have underperformed the Zacks Large Cap Pharmaceuticals industry year to date, increasing +1.8% vs. a gain of +7.2%.",0.8323633670806885,0.13853347301483154,0.029103102162480354,positive,0.6938298940658569
13,2018-10-04 23:16:00,"However, Bristol-Myers' blockbuster immuno-oncology drug Opdivo continues to maintain momentum.",0.905296802520752,0.014655119739472866,0.0800480991601944,positive,0.8906416893005371
14,2018-10-04 23:16:00,"Opdivo's performance is being boosted by the uptake in new indications, first line renal cell and adjuvant melanoma.",0.9500636458396912,0.015041302889585495,0.03489494323730469,positive,0.9350223541259766
15,2018-10-04 23:16:00,Several label expansion applications for Opdivo are under review in the United States and Europe.,0.06877119839191437,0.008834661915898323,0.9223940968513489,neutral,0.059936538338661194
16,2018-10-04 23:16:00,The drug was recently approved for small cell lung cancer in the United States and melanoma in Europe.,0.6385687589645386,0.012296169996261597,0.34913501143455505,positive,0.6262725591659546
17,2018-10-04 23:16:00,Potential approval in other indications will further boost the prospects of this blockbuster drug.,0.9477016925811768,0.01676386035978794,0.03553437441587448,positive,0.9309378266334534
18,2018-10-04 23:16:00,Eliquis is expected to drive further growth in 2018 driven by increases in market share in the novel oral anticoagulant (NOAC) market.,0.9292738437652588,0.012958596460521221,0.057767510414123535,positive,0.9163152575492859
19,2018-10-04 23:16:00,The label expansion of other drugs like Sprycel and Empliciti also bode well for the company.,0.9342460036277771,0.013918817043304443,0.05183522030711174,positive,0.9203271865844727
20,2018-10-04 23:16:00,"However, pricing concerns, stiff competition in the immuno-oncology space are expected to remain an overhang.",0.14041945338249207,0.379086971282959,0.48049360513687134,neutral,-0.23866751790046692
21,2018-10-04 23:16:00,(You can read the full research report on Bristol-Myers here >>> ).,0.013764891773462296,0.012010612525045872,0.9742245078086853,neutral,0.0017542792484164238
22,2018-10-04 23:16:00,"Buy-ranked Costco 's shares have outperformed the Zacks Discount Retail industry over the past six months, gaining +25.9% versus the industry's +19.2% increase.",0.9296433329582214,0.051515474915504456,0.018841218203306198,positive,0.8781278729438782
23,2018-10-04 23:16:00,Costco continues to be one of the dominant retail wholesalers based on the breadth and quality of merchandise offered.,0.4792155921459198,0.009499073959887028,0.5112853050231934,neutral,0.46971651911735535
24,2018-10-04 23:16:00,The Zacks analyst thinks the stock has been gaining from sturdy comps performance and upbeat results.,0.9537553191184998,0.021354783326387405,0.024889828637242317,positive,0.9324005246162415
25,2018-10-04 23:16:00,"Notably, comps for fourth-quarter fiscal 2018 advanced 9.5% year over year, while revenues improved 5%.",0.9530531764030457,0.02152896299958229,0.025417862460017204,positive,0.9315242171287537
26,2018-10-04 23:16:00,"In fact, this marks the company's sixth consecutive revenue beat.",0.9312755465507507,0.027398882433772087,0.04132557287812233,positive,0.9038766622543335
27,2018-10-04 23:16:00,"Undoubtedly, the robust performance indicates that the company's growth efforts have been fueling traffic across both the online and brick-and-mortar platforms.",0.9388510584831238,0.016079258173704147,0.045069620013237,positive,0.9227718114852905
28,2018-10-04 23:16:00,"Moreover, the company is augmenting merchandise offerings and delivery services to further boost e-commerce sales.",0.9508553743362427,0.015686271712183952,0.03345830738544464,positive,0.9351691007614136
29,2018-10-04 23:16:00,"However, lower core merchandise margins have been weighing on Costco's gross margin.",0.023869264870882034,0.9573349356651306,0.01879584975540638,negative,-0.9334656596183777
30,2018-10-04 23:16:00,"Further, rising SG&A expenses, stiff competition and unfavorable currency changes continue to pose threats.",0.04806667938828468,0.8391444087028503,0.11278897523880005,negative,-0.791077733039856
31,2018-10-04 23:16:00,(You can read the full research report on Costco here >>> ).,0.011449351906776428,0.012908922508358955,0.9756417870521545,neutral,-0.0014595706015825272
32,2018-10-04 23:16:00,"Other noteworthy reports we are featuring today include Raytheon (RTN), Ecolab (ECL) and Ameriprise Financial (AMP).",0.03800763189792633,0.0055487630888819695,0.9564436078071594,neutral,0.032458867877721786
33,2018-10-04 23:16:00,"It's hard to believe, even for us at Zacks.",0.08736173063516617,0.254048228263855,0.6585900187492371,neutral,-0.1666865050792694
34,2018-10-04 23:16:00,"But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.",0.5075593590736389,0.04700726270675659,0.4454334080219269,positive,0.4605520963668823
35,2018-10-04 23:16:00,And this outperformance has not just been a recent phenomenon.,0.07535909861326218,0.015217346139252186,0.9094235301017761,neutral,0.060141753405332565
36,2018-10-04 23:16:00,Over the years it has been remarkably consistent.,0.6927107572555542,0.013971779495477676,0.29331743717193604,positive,0.6787389516830444
37,2018-10-04 23:16:00,"From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over.",0.7464389204978943,0.10755439102649689,0.14600670337677002,positive,0.6388845443725586
38,2018-10-04 23:16:00,Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.,0.5744941830635071,0.01052891369909048,0.41497692465782166,positive,0.5639652609825134
39,2018-10-04 23:16:00,Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings.,0.1108352467417717,0.007436841260641813,0.881727933883667,neutral,0.1033984050154686
40,2018-10-04 23:16:00,He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports.,0.026142945513129234,0.011532393284142017,0.9623246192932129,neutral,0.014610552228987217
41,2018-10-04 23:16:00,"If you want an email notification each time Sheraz publishes a new article, please click here>>>

Strength in the Global Institutional segment is likely to aid Ecolab's top line in the quarters to come.",0.9445971250534058,0.019230492413043976,0.03617238253355026,positive,0.9253666400909424
42,2018-10-04 23:16:00,"However, the Zacks analyst is apprehensive about cutthroat competition in the MedTech space.",0.027362443506717682,0.902234673500061,0.0704028531908989,negative,-0.8748722076416016
43,2018-10-04 23:16:00,"Per the Zacks analyst, Ameriprise is well poised for top-line growth given its strategic restructuring efforts and a well-diversified portfolio.",0.9107597470283508,0.01295076496899128,0.07628952711820602,positive,0.8978089690208435
44,2018-10-04 23:16:00,Its capital deployment activities also seem impressive.,0.7842013239860535,0.011965296231210232,0.20383335649967194,positive,0.7722360491752625
45,2018-10-04 23:16:00,"Per the Zacks analyst, Microchip's expanding product portfolio, robust demand for microcontrollers and collaboration with Amazon Web services will drive top-line growth.",0.9321220517158508,0.013474544510245323,0.05440344288945198,positive,0.9186475276947021
46,2018-10-04 23:16:00,"Per the Zacks analyst, International Flavors & Fragrances will benefit from growing demand in flavors and fragrances markets, particularly in emerging markets as well as its cost cutting efforts.",0.9432801008224487,0.014328628778457642,0.04239127039909363,positive,0.9289515018463135
47,2018-10-04 23:16:00,"Per the Zacks analyst, improvement in insurance in force, driven by increase in new business, will continue to boost MGIC Investment's top line.",0.9577949047088623,0.018254069611430168,0.023951014503836632,positive,0.9395408630371094
48,2018-10-04 23:16:00,"Per the Zacks analyst, Unum is set to benefit from improving premiums on better sales trends, solid persistency and favorable risk results.",0.9593771696090698,0.0188888106495142,0.0217339638620615,positive,0.940488338470459
49,2018-10-04 23:16:00,"Per the Zacks analyst, Rite Aid strives to capitalize on growth potential through its standalone strategy.",0.8295899629592896,0.010167296044528484,0.16024276614189148,positive,0.8194226622581482
50,2018-10-04 23:16:00,"Per the Zacks analyst, Raytheon enjoys solid order inflows from overseas customers courtesy its combat-proven defense products.",0.9540817141532898,0.01692708022892475,0.028991179540753365,positive,0.9371546506881714
51,2018-10-04 23:16:00,Rising demand from Gulf and Asia-Pacific is also a key revenue driver.,0.875983476638794,0.014759393408894539,0.10925713926553726,positive,0.8612240552902222
52,2018-10-04 23:16:00,"Per the Zacks analysts, Darden's sales boosting initiatives like developing core menu and technology-driven moves are expected to boost the top line.",0.9529352784156799,0.01974552683532238,0.02731923572719097,positive,0.9331897497177124
53,2018-10-04 23:16:00,The company's cost control efforts also bode well.,0.8710228800773621,0.013777409680187702,0.11519971489906311,positive,0.8572454452514648
54,2018-10-04 23:16:00,"Per the Zacks analyst, improved store sales & digital initiatives are aiding CarMax's comparable-store used vehicle sales.",0.9557311534881592,0.017852023243904114,0.026416856795549393,positive,0.9378791451454163
55,2018-10-04 23:16:00,The rise in sales is getting complemented by aggressive store expansion.,0.9386968612670898,0.016325028613209724,0.044978074729442596,positive,0.9223718047142029
56,2018-10-04 23:16:00,"Per the Zacks analyst, the company's drug Feraheme currently competes with IV iron replacement therapies as well as their generic versions which could limit sales for the drug.",0.02065172605216503,0.9389865398406982,0.04036178067326546,negative,-0.9183348417282104
57,2018-10-04 23:16:00,"Per the Zacks analyst, higher SG&A expenses have been taking a toll on Hibbett's operating margin, which remains a concern in fiscal 2019.",0.025652410462498665,0.9576386213302612,0.016708968207240105,negative,-0.9319862127304077
58,2018-10-04 23:16:00,This is hurting the company's overall profitability as well.,0.018698543310165405,0.96507728099823,0.016224127262830734,negative,-0.9463787078857422
59,2018-10-04 23:16:00,"Per the Zacks analyst, America Movil is striving hard to increase its smartphone sales through promotional discounts and subsidized offers, which are hurting its margins and overall profitability.",0.023799171671271324,0.9603308439254761,0.015869980677962303,negative,-0.936531662940979
60,2018-10-04 23:16:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
61,2018-10-04 23:16:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
62,2018-10-04 23:16:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
63,2018-10-04 23:16:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
